Search Result

Results for "

THR-β

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Thyroid Hormone Receptor (25) Acetyl-CoA Carboxylase (1) AMPK (1) Calcium Channel (1) FXR (1) Interleukin Related (1) Isotope-Labeled Compounds (1) LDLR (1) Mitochondrial Metabolism (1) Potassium Channel (1) Sodium Channel (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Endocrinology (5) Infection (1) Inflammation/Immunology (6) Metabolic Disease (18) Neurological Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Thyroid Hormone Receptor Ser/Thr Kinase Ser/Thr Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12216

Resmetirom 20+ Cited Publications MGL-3196; VIA-3196	Thyroid Hormone Receptor	Cardiovascular Disease Endocrinology
Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC₅₀ value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis .

HY-143613

THR-β agonist 2	Thyroid Hormone Receptor	Metabolic Disease
THR-β agonist 2 is a potent agonist of *THR-β. THR-β* agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .

HY-168046

ALG-055009	Thyroid Hormone Receptor	Metabolic Disease
ALG-055009 is a selective and orally active Thyroid Hormone Receptor Beta (THR-β) agonist with an EC₅₀ of 0.063 μM. ALG-055009 binds to the T3 hormone pocket of human THR-β, forming polar interactions with protein residues. ALG-055009 can lower total cholesterol levels in rats on a high-fat diet. ALG-055009 exhibits high metabolic stability, good permeability, a long in vivo half-life, and limited drug-drug interaction liability. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease .

HY-147055

THR-β agonist 5	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 5 is a *THR-β* agonist. THR-β agonist 5 can be used for the research of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis .

HY-178015

THR-β agonist 11	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 11 is an orally active and selective thyroid hormone receptor (THR-β) agonist. THR-β agonist 11 shows potent cholesterol-lowering activity in cholesterol-fed rats. THR-β agonist 11 significantly reduces serum total TG, LDL-cholesterol, liver total TC and TG levels, and alleviates hepatic steatosis, inflammation and fibrosis in HFD-CCl4-induced Metabolic dysfunction-associated steatohepatitis (MASH) model mice. THR-β agonist 11 can be used for the study of metabolic dysfunction-associated steatohepatitis (MASH) and other fibrotic diseases .

HY-120026

KB130015 1 Publications Verification KB015	Thyroid Hormone Receptor Calcium Channel Potassium Channel Sodium Channel	Cardiovascular Disease
KB130015 (KB015) is an orally active and potent ThRα and *ThRβ* (thyroid hormone receptor) inhibitor, with IC₅₀ values of 4.5 and 5.1 μM, respectively. KB130015 markedly slows the kinetics of inactivation of Na ⁺ channels. KB130015 activates hERG1 channels (EC₅₀ = 12.2 μM) and large-conductance Ca ²⁺-activated K ⁺ (BKCa) channels formed by hSlo1 (α) subunits in HEK 293 cells. KB130015 has antiarrhythmic properties. KB130015 can be used for the study of cardiovascular disease .

HY-163945

ZTA-261	Thyroid Hormone Receptor	Metabolic Disease
ZTA-261 is a highly selective and low toxic thyroid hormone receptor β subtype (THR-β) agonist (IC₅₀=6.3 nM) that reduces body weight and visceral fat through a liothyronine (HY-A0070A) mediated pathway. ZTA-261 can be used in the study of lipid metabolism and obesity prevalence .

HY-149218

THR-β agonist 6	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 6 is an orally active, selective thyroid hormone receptor β (THR-β) agonist with EC₅₀s of 0.03 μM and 0.22 μM for THR-β and THR-α, respectively. THR-β agonist 6 exhibits an xcellent liver-to-serum ratio of 93:1 in mice. THR-β agonist 6 has the potential for nonalcoholic steatohepatitis (NASH) research .

HY-175676

THR-β agonist 10	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 10 is an orally active and selective *THR-β* agonist, with an EC₅₀ of 11 nM. THR-β agonist 10 significantly reduces ALT (Alanine Aminotransferase), TC (Total Cholesterol), and LDL-C (Low-Density Lipoprotein Cholesterol) levels, and improves steatosis, ballooning, inflammation and fibrosis in the metabolic dysfunction-associated steatohepatitis (MASH) mouse model. THR-β agonist 10 can be used for the study of MASH .

HY-174887

THR-β agonist 9	Thyroid Hormone Receptor AMPK Acetyl-CoA Carboxylase Mitochondrial Metabolism	Metabolic Disease
THR-β agonist 9 is a potent, selective, and His435 mutation-sensitive *THR-β* (EC₅₀: 3.2 nM) agonist. THR-β agonist 9 has moderate selectivity (approximately 10-fold) and good activation capacity (EC₅₀: 134.2 nM to 515.5 nM) for multiple His435 mutants (H435A, H435Y, and H435R). THR-β agonist 9 has the potential to be used in the study of dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), or resistance to thyroid hormone (RTH) .

HY-142441

THR-β agonist 1	Thyroid Hormone Receptor	Endocrinology
THR-β Agonist 1 is a potent and selective agonist of *THRβ. Thyroid hormone receptor mediates the physiological activity of thyroid hormones which plays a key role in normal growth and development of the body and in maintaining metabolic balance. THR-β* Agonist 1 has the potential for the research of thyroid hormone receptor-related diseases (extracted from patent WO2021104288A1, compound 2) .

HY-172661

Kylo-0603	Thyroid Hormone Receptor Interleukin Related LDLR	Infection Metabolic Disease
KYLO-0603 is an orally active, selective THR-β agonist (EC₅₀ : 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .

HY-160416

THR-β modulator-2	Thyroid Hormone Receptor	Endocrinology
THR-β modulator-2 (compound 40) is a thyroid hormone receptor β (THR-β) modulator .

HY-143613A

THR-β agonist 2 diacetate	Thyroid Hormone Receptor	Metabolic Disease
THR-β agonist 2 (Compound 3) diacetate is a selective thyroid hormone receptor β (THRβ) agonist with an EC₅₀ of 1.42 μM. THR-β agonist 2 diacetate can regulate the biological pathways mediated by thyroid hormones. THR-β agonist 2 diacetate can be used for the study of metabolic diseases .

HY-143614

THR-β agonist 3	Thyroid Hormone Receptor	Metabolic Disease
THR-β agonist 3 is a potent agonist of *THR-β. THR-β* agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .

HY-142917

THR-β agonist 4	Thyroid Hormone Receptor	Metabolic Disease
THR-β agonist 4 is a potent agonist of *THR-β. THR-β* agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .

HY-160266

THR-β agonist 7	Thyroid Hormone Receptor	Metabolic Disease Cancer
THR-β agonist-1 (Example 2) is a *THR-β* agonist, with EC₅₀ values of 52 nM and 1017 nM for THR-β and THR-α, respectively .

HY-153637

THR-β modulator-1	Thyroid Hormone Receptor	Endocrinology
THR-β modulator-1 (compound 1a) is a potent thyroid hormone receptor β modulator. THR-β modulator-1 can be used in research of thyroid hormone receptor related disorders .

HY-171013

THR-β agonist 8	Thyroid Hormone Receptor	Neurological Disease Metabolic Disease
THR-β agonist 8 (Compound 1) is an orally active agonist of TRα and TRβ. THR-β agonist 8 is promising for research of thyroid hormone-related diseases .

HY-180642

THR-β modulator-3	Thyroid Hormone Receptor	Metabolic Disease
THR-β modulator-3 (Compound 75-2) is a *THR-β* modulator. THR-β modulator-3reduces total fat mass, body weight. THR-β modulator-3 improves obesity .

HY-118978

PF-00277343	Thyroid Hormone Receptor	Endocrinology
PF-00277343 is a selective and skin-penetrable *THR-β* (K_i: 0.51 nM for THR-β, 8.0 nM for THR-α) agonist. PF-00277343 is effective against androgenetic alopecia in animal models .

HY-153535

THRβ receptor agonist-1	Thyroid Hormone Receptor	Metabolic Disease
THRβ receptor agonist-1 is a THRβ receptor agonist .

HY-174805

THRβ receptor agonist-2	Thyroid Hormone Receptor	Metabolic Disease
THRβ receptor agonist-2 (Example 7-4) is a THRβ receptor agonist. THRβ receptor agonist-2 can be used for research of liver disorder or a cardiometabolic disease .

HY-172439S

Simedeutirom	Isotope-Labeled Compounds Thyroid Hormone Receptor	Metabolic Disease
Simedeutirom is the agonist for thyroid hormone beta receptor (THRβ) and can be used for researchs of metabolic diseases, such as obesity and diabetes mellitus .

HY-179703

FXR agonist 15	FXR	Inflammation/Immunology
FXR agonist 15 is a selective, potent and orally active farnesoid X receptor (FXR) agonist with EC₅₀ of 0.76 μM. FXR agonist 15 exhibits no obvious activation on other nuclear receptors including LXRα/β, PXR, PPARα/β/γ, THR-β, with EC₅₀ values all >10 μM. FXR agonist 15 can alleviate steatosis, lobular inflammation, hepatocyte ballooning and liver fibrosis. FXR agonist 15 can be used for the research of nonalcoholic steatohepatitis (NASH) .

HY-182769

TRβ agonist-4	Thyroid Hormone Receptor	Inflammation/Immunology
TRβ agonist-4 is an orally bioavailable, liver-targeted selective agonist of hTHR-β (EC₅₀=6.0 nM), with a 105.3-fold selectivity over *THR-α*. TRβ agonist-4 exists in multiple crystal forms, including Form A, Form B, Form C, Form D, Form E, as well as an amorphous form. TRβ agonist-4 can be used for research related to non-alcoholic steatohepatitis (NASH) .

Cat. No.	Product Name	Chemical Structure

HY-160266

THR-β agonist 7
THR-β agonist-1 (Example 2) is a *THR-β* agonist, with EC₅₀ values of 52 nM and 1017 nM for THR-β and THR-α, respectively .

HY-172439S

Simedeutirom
Simedeutirom is the agonist for thyroid hormone beta receptor (THRβ) and can be used for researchs of metabolic diseases, such as obesity and diabetes mellitus .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.